The DOI matches its Crossref record; 411 of the 411 references it cites were found in a registry or an index.
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Open accessAbstract
T cells play a critical role in cancer control, but a range of potent immunosuppressive mechanisms can be upregulated in the tumor microenvironment (TME) to abrogate their activity. While various immunotherapies (IMTs) aiming at re-invigorating the T-cell-mediated anti-tumor response, such as immune checkpoint blockade (ICB), and the adoptive cell transfer (ACT) of natural or gene-engineered ex vivo expanded tumor-specific T cells, have led to unprecedented clinical responses, only a small proportion of cancer patients benefit from these treatments. Important research efforts are thus underway to identify biomarkers of response, as well as to develop personalized combinatorial approaches that can target other inhibitory mechanisms at play in the TME. In recent years, adenosinergic signaling has emerged as a powerful immuno-metabolic checkpoint in tumors. Like several other barriers in the TME, such as the PD-1/PDL-1 axis, CTLA-4, and indoleamine 2,3-dioxygenase (IDO-1), adenosine plays important physiologic roles, but has been co-opted by tumors to promote their growth and impair immunity. Several agents counteracting the adenosine axis have been developed, and pre-clinical studies have demonstrated important anti-tumor activity, alone and in combination with other IMTs including ICB and ACT. Here we review the regulation of adenosine levels and mechanisms by which it promotes tumor growth and broadly suppresses protective immunity, with extra focus on the attenuation of T cell function. Finally, we present an overview of promising pre-clinical and clinical approaches being explored for blocking the adenosine axis for enhanced control of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–411 of 411
Cholera Toxin Directly Enhances IL-17A Production from Human CD4+ T Cells
Tsai, H., & Wu, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301079 · Cited by 17
Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1268308 · Cited by 17
Distinctive immunoregulatory effects of adenosine on T cells of older humans
Hesdorffer, C. S., Malchinkhuu, E., Biragyn, A., Mabrouk, O. S., Kennedy, R. T., Madara, K., Taub, D. D., Longo, D. L., Schwartz, J. B., Ferrucci, L., et al. (2011) · The FASEB Journal · doi:10.1096/fj.11-197046 · Cited by 16
Mechanisms of Activation by CREB and CREM: Phosphorylation, CBP, and a Novel Coactivator, ACTPreprint
Fimia, G. M., Cesare, D. D., & Sassone‐Corsi, P. (1998) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1998.63.631 · Cited by 15
Özüyaman, B., Ding, Z., Buchheiser, A., Koszałka, P., Braun, N., Gödecke, A., Decking, U. K. M., Zimmermann, H., & Schrader, J. (2006) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0045-x · Cited by 15
Adenosine regulates radiation therapy-induced anti-tumor immunity
Wennerberg, E., Kawashima, N., & Demaria, S. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p378 · Cited by 15
CBirTox is a selective antigen-specific agonist of the Treg-IgA-microbiota homeostatic pathway
Alexander, K. L., Katz, J., & Elson, C. O. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181866 · Cited by 14
Adenosine prevents neutrophil adhesion to human endothelial cells after hypoxia/reoxygenation
Kilian, J. G., Nakhla, S., Sieveking, D. P., et al. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.03.010 · Cited by 13
Heightened NTPDase-1/CD39 expression and angiogenesis in radiation proctitis
Sheth, S. G., Bleibel, W., Thukral, C., A-Rahim, Y. I., Beldi, G., Csizmadia, E., & Robson, S. C. (2009) · Purinergic Signalling · doi:10.1007/s11302-009-9154-2 · Cited by 12
Abstract 1476: A therapeutic antibody that inhibits CD73 activity by dual mechanisms
Barnhart, B. C., Sega, E. I., Yamniuk, A. P., Hatcher, S. V., Lei, M., Ghermazien, H., Lewin, A. C., Wang, X.-T., Huang, H., Zhang, P., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-1476 · Cited by 11
Fons, P., Esquerré, M., Versluys, S., Mambrini, G., Paillasse, M. R., Bell, A., Schreyer, A. M., Cox, R., Bickerton, R., Lisztwan, J. H., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3970 · Cited by 5
Cited by
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
Metadata
- Authors
- Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-06
- Volume
- 10
- Pages
- 925-925
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2947747173
- Cited by
- 420
- References
- 411
- FWCI
- 33.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.